natgillin/translations-raw huggingface dataset:
Meningitis, opportunistic infections (such as invasive fungal infections [pneumocystosis, histoplasmosis, aspergillosis, coccidioidomycosis, cryptococcosis, blastomycosis], bacterial infections [atypical mycobacterial, listeriosis, salmonellosis], and viral infections [cytomegalovirus]), parasitic infections, hepatitis B reactivation.
listerioza, salmoneloza] i virusne infekcije [citomegalovirus]), parazitske infekcije, reaktivacija hepatitisa B
Remove the pen from the injection site.
12. Uklonite brizgalicu s mjesta primjene.
Tel: +386 1 519 29 22 info@oktal-pharma.si
OKTAL PHARMA d.o.o. Tel: +386 1 519 29 22 info@oktal-pharma.si
Table 1 Adverse reactions in clinical studies and from post-marketing experience
Nuspojave u kliničkim ispitivanjima i nakon stavljanja lijeka u promet
• You should receive recommended vaccinations before starting Remsima treatment.
• Prije početka liječenja lijekom Remsima trebate primiti sva preporučena cjepiva.
Mean baseline NAPSI scores were 4.6 and 4.3 in infliximab and placebo group.
Prosječni početni NAPSI rezultati iznosili su 4,6 u skupini liječenoj infliksimabom i
• Tell your doctor straight away if you get symptoms of liver problems during treatment with Remsima.
• Odmah obavijestite Vašeg liječnika ako dobijete simptome jetrenih tegoba za vrijeme liječenja lijekom Remsima.
Clinical response at Week 8a Clinical response at Week 30a Sustained response (clinical response at both Week 8 and Week 30)
Postotak ispitanika s kliničkim odgovorom i održanim kliničkim odgovorom Klinički odgovor u 8. tjednua
Insert the syringe into the injection site (see Figure E).
Ubodite iglu štrcaljke u odabrano mjesto primjene (vidjeti Sliku E).
Juvenile rheumatoid arthritis patients
Pedijatrijska populacija Bolesnici s juvenilnim reumatoidnim artritisom
A total of 306 patients received 3 doses of infliximab 5 mg/kg at week 0, 2 and 6.
3 doze infliksimaba u dozi od 5 mg/kg u 0., 2. i 6. tjednu.
Elderly
Ungverjaland
Tell your doctor straight away if you get signs of TB during treatment with Remsima.
Odmah obavijestite svog liječnika ako tijekom liječenja lijekom Remsima dobijete znakove tuberkuloze.
Week 22
6. tjedan 22. tjedan
Do not recap the pen.
nemojte ponovno primijeniti istu brizgalicu..
Paediatric Crohn's disease patients
Crohnova bolest u pedijatrijski h bolesnika
How to use Remsima
Kako primjenjivati lijek Remsima
Remsima 120 mg solution for injection in pre-filled pen Remsima 120 mg solution for injection in single-use pre-filled pen for patient use containing a pre-filled syringe.
Remsima 120 mg otopina za injekciju u napunjenoj brizgalici Remsima 120 mg otopina za injekciju u napunjenoj brizgalici za jednokratnu primjenu od strane bolesnika.
Each pack contains 1 pre-filled pen with 2 alcohol pads, 2 pre-filled pens with 2 alcohol pads or 4 pre-filled pens with 4 alcohol pads.
Jedno pakiranje sadrži 1 napunjenu brizgalicu s 2 jastučića natopljena alkoholom, 2 napunjene brizgalice s 2 jastučića natopljena alkoholom ili 4 napunjene brizgalice s 4 jastučića natopljena alkoholom.
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
BROJ SERIJE<, OZNAKE DONACIJE I PROIZVODA>
The syringe is made from type I glass with a plunger stopper (flurotec-coated elastomer) and needle with a rigid needle shield.
I s čepom klipa (elastomer presvučen flurotekom) i iglom s čvrstim štitnikom igle.
• Do not shake the pen at any time.
• Nemojte nikada tresti brizgalicu.
The primary endpoints were the reduction of signs and symptoms as assessed by the ACR criteria (ACR20 for ATTRACT, landmark ACR-N for ASPIRE), the prevention of structural joint damage, and the improvement in physical function.
ATTRACT, granična vrijednost ACR-N za ASPIRE), sprečavanje strukturnog oštećenja zglobova te poboljšanje funkcionalne sposobnosti.
In clinical studies using single and multiple infliximab doses ranging from 1 to 20 mg/kg, antibodies to infliximab were detected in 14% of patients with any immunosuppressant therapy, and in 24% of patients without immunosuppressant therapy.
protutijela protiv infliksimaba otkrivena su u 14% bolesnika koji su primali neku imunosupresivnu terapiju te u 24% bolesnika koji nisu primali imunosupresivnu terapiju.
• 2 prefilled syringes with automatic needle guard (1 mL sterile solution) with 2 alcohol pads.
• 2 napunjene štrcaljke s automatskim štitnikom igle (1 ml sterilne otopine) s 2 jastučića natopljena alkoholom.
Name patient:
Zaštićeni naziv:
EU/1/13/853/001 1 vial EU/1/13/853/002 2 vials EU/1/13/853/003 3 vials EU/1/13/853/004 4 vials EU/1/13/853/005 5 vials
EU/1/13/853/001 1 bočica EU/1/13/853/002 2 bočice EU/1/13/853/003 3 bočice EU/1/13/853/004 4 bočice EU/1/13/853/005 5 bočica
Remove the syringe from the injection site (see Figure G).
11. Uklonite štrcaljku s mjesta primjene (vidjeti Sliku G).
• Do not reuse the pen.
• Nemojte ponovno primijeniti istu brizgalicu.
Each pack contains 1 pre-filled syringe with 2 alcohol pads, 2 pre-filled syringes with 2 alcohol pads or 4 pre-filled syringes with 4 alcohol pads.
Jedno pakiranje sadrži 1 napunjenu štrcaljku s 2 jastučića natopljena alkoholom, 2 napunjene štrcaljke s 2 jastučića natopljena alkoholom ili 4 napunjene štrcaljke s 4 jastučića natopljena alkoholom.
Remsima is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen ultra-violet A (PUVA) (see section 5.1).
Psorijaza Remsima je indicirana za liječenje umjerene do teške plak psorijaze u odraslih bolesnika u kojih je druga sustavna terapija, uključujući ciklosporin, metotreksat ili psoralen ultraljubičastu
Solution for injection 1 pre-filled pen with 2 alcohol pads 2 pre-filled pens with 2 alcohol pads 4 pre-filled pens with 4 alcohol pads
1 napunjena brizgalica s 2 jastučića natopljena alkoholom 2 napunjene brizgalice s 2 jastučića natopljena alkoholom 4 napunjene brizgalice s 4 jastučića natopljena alkoholom
Remsima is a clear to opalescent, colourless to pale brown solution which is supplied as a single use pre-filled pen.
Lijek Remsima je bistra do opalescentna, bezbojna do svijetlosmeđa otopina koja dolazi u napunjenoj brizgalici za jednokratnu primjenu.
In patients treated with infliximab, an invasive fungal infection such as aspergillosis, candidiasis, pneumocystosis, histoplasmosis, coccidioidomycosis or blastomycosis should be suspected if they develop a serious systemic illness, and a physician with expertise in the diagnosis and treatment of invasive fungal infections should be consulted at an early stage when investigating these patients.
U bolesnika liječenih infliksimabom u kojih se razvije ozbiljna sistemska bolest treba posumnjati na neku invazivnu gljivičnu infekciju poput aspergiloze, kandidijaze, pneumocistoze, histoplazmoze,
‘Re-administration' below and section 4.4).
(vidjeti dio 4.4).
Tell your doctor straight away if you get symptoms of a nerve disease during treatment with Remsima.
Odmah obavijestite svog liječnika ako tijekom liječenja lijekom Remsima dobijete simptome neke bolesti živčanog sustava.
• 1 prefilled syringe with automatic needle guard (1 mL sterile solution) with 2 alcohol pads.
• 1 napunjena štrcaljka s automatskim štitnikom igle (1 ml sterilne otopine) s 2 jastučića natopljena alkoholom.
A total of 573 patients with moderately to severely active Crohn's disease (CDAI ≥220 ≤400) received a single infusion of 5 mg/kg at week 0.
Ukupno je 573 bolesnika s umjerenom do teškom, aktivnom Crohnovom bolešću (CDAI ≥ 220 i
Tell your doctor straight away if you get signs of infection during treatment with Remsima.
Odmah obavijestite svog liječnika ako tijekom liječenja lijekom Remsima dobijete simptome infekcije.
In psoriasis patients treated with infliximab as a maintenance regimen in the absence of concomitant immunomodulators, approximately 28% developed antibodies to infliximab (see section 4.4: "Infusion reactions and hypersensitivity").
Približno 28% bolesnika s psorijazom liječenih infliksimabom kao terapijom održavanja bez istodobnog liječenja imunomodulatorima razvilo je protutijela protiv infliksimaba
Remsima may be stored at temperatures up to a maximum of 25°C for a single period of up to 6 months, but not exceeding the original expiry date.
Remsima se može čuvati na temperaturi do najviše 25°C neprekinuto tijekom razdoblja od najviše
• 4 prefilled syringes (1 mL sterile solution) with 4 alcohol pads.
• 4 napunjene štrcaljke (1 ml sterilne otopine) s 4 jastučića natopljena alkoholom.
Each 1 ml single dose pre-filled syringe contains 120 mg of infliximab.
Jedna napunjena brizgalica s jednokratnom dozom od 1 ml sadrži 120 mg infliksimaba.
The proportions of patients in sustained response and sustained remission at week 54 were greater in the combined infliximab treatment group than in the placebo treatment group (37.9% vs. 14.0%, p<0.001; and 20.2% vs. 6.6%, p<0.001, respectively).
(zbirni podaci) nego u skupini koja je primala placebo (37,9% naspram 14,0%, p < 0,001; odnosno 20,2% naspram 6,6%, p < 0,001).
• 1 prefilled syringe (1 mL sterile solution) with 2 alcohol pads.
• 1 napunjena brizgalica (1 ml sterilne otopine) s 2 jastučića natopljena alkoholom.
Teл.
(TNFβ).
Re-administration for Crohn's disease and rheumatoid arthritis If the signs and symptoms of disease recur, infliximab can be re-administered within 16 weeks following the last infusion.
Ako se ponovno pojave znakovi i simptomi bolesti, infliksimab se može ponovno primijeniti unutar
• 4 prefilled pens (1 mL sterile solution) with 4 alcohol pads.
• 4 napunjene brizgalice (1 ml sterilne otopine) s 4 jastučića natopljena alkoholom.
In patients who have several or significant risk factors for tuberculosis and have a negative test for latent tuberculosis, antituberculosis therapy should be considered before the initiation of infliximab.
Treba razmotriti primjenu antituberkulozne terapije prije početka liječenja lijekom infliksimabom u bolesnika koji imaju brojne ili značajne čimbenike rizika za tuberkulozu, a rezultati testa na latentnu tuberkulozu su im negativni.
An updated RMP should be submitted:
Lijek Remsima treba primjenjivati:
Tel: +34 93 700 25 25
KERN PHARMA, S.L. Tel: + 34 93 700 25 25
• Chills, a build-up of fluid under the skin causing swelling
• zimica, nakupljanje tekućine ispod kože koje uzrokuje oticanje • osjećaj utrnulosti i trnci.
Based on an observational study from Northern Europe, an increased risk (OR, 95% CI; p-value) for C-section (1.50, 1.14-1.96; p = 0.0032), preterm birth (1.48, 1.05-2.09; p = 0.024), small for gestational age (2.79, 1.54-5.04; p = 0.0007), and low birth weight (2.03, 1.41-2.94; p = 0.0002) was observed in women exposed during pregnancy to infliximab (with or without immunomodulators/corticosteroids, 270 pregnancies) as compared to women exposed to immunomodulators and/or corticosteroids only (6,460 pregnancies).
95% CI; p-vrijednost) za carski rez (1,50; 1,14-1,96; p = 0,0032), prijevremeni porođaj (1,48;
Some of these infections have been fatal; the most frequently reported opportunistic infections with a mortality rate of >5% include pneumocystosis, candidiasis, listeriosis and aspergillosis.
> 5% uključuju pneumocistozu, kandidijazu, listeriozu i aspergilozu.
Week 54 among patients who were receiving corticosteroids at baseline.
primijećeno je nakon 54 tjedana u svim skupinama bolesnika koji su primali infliksimab (Tablica 3).
The primary endpoints were the reduction of signs and symptoms as assessed by the American College of Rheumatology criteria (ACR20 for ATTRACT, landmark ACR-N for ASPIRE), the prevention of structural joint damage, and the improvement in physical function.
Primarne mjere ishoda bile su smanjenje znakova i simptoma prema kriterijima Američkog reumatološkog društva (engl.
• 2 prefilled syringes (1 mL sterile solution) with 2 alcohol pads.
• 2 napunjene brizgalice (1 ml sterilne otopine) s 2 jastučića natopljena alkoholom.
• Sharps disposal container* *Items not included in the carton.
Sharpove bodovne skale) prikazani su u Tablici
• Bleeding in the stomach or intestines, diarrhoea, indigestion, heartburn, constipation
šaka ili usana, disfagiju, urtikariju, grlobolju i glavobolju.
After reconstitution and dilution:
Nakon pripreme otopine,
• Syringe
• štrcaljku
At
Od
Percentage of subjects in clinical response and in sustained clinical response
Postotak ispitanika u kliničkoj remisiji i održanoj remisiji Klinička remisija u 8. tjednua
Remsima is indicated for treatment of severe, active Crohn's disease in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies.
Remsima je indicirana za liječenje teške, aktivne Crohnove bolesti u djece i adolescenata u dobi između 6 i 17 godina, koji nisu odgovorili na konvencionalnu terapiju uključujući kortikosteroid,
• Signs of a heart problem such as chest discomfort or pain, arm pain, stomach pain, shortness of breath, anxiety, lightheadedness, dizziness, fainting, sweating, nausea (feeling sick),
• Znakove srčanih problema kao što su nelagoda ili bol u prsnom košu, bol u ruci, bol u trbuhu,
In the second clinical study (IMPACT 2), efficacy and safety of infliximab were studied in 200 patients with active psoriatic arthritis (≥5 swollen joints and ≥5 tender joints).
200 bolesnika s aktivnim psorijatičnim artritisom (≥ 5 otečenih zglobova i ≥ 5 bolnih zglobova).
Circulatory failure, petechia, vasospasm Respiratory, thoracic and mediastinal disorders Very common
zatajenje cirkulacije, petehije, vazospazam
Subcutaneous use Read the package leaflet before use.
NAČIN I PUT(EVI) PRIMJENE LIJEKA Prije uporabe pročitajte uputu o lijeku.
10 mg/kg q 4 wks
10 mg/kg Zbirni podaci
Maintenance treatment in moderately to severely active Crohn's disease in adults The efficacy of repeated infusions with infliximab was studied in a 1-year clinical study (ACCENT I).
Djelotvornost ponovljenih infuzija infliksimaba ispitivala se u jednogodišnjem kliničkom ispitivanju
If response was lost during maintenance treatment, crossing over to a higher dose (10 mg/kg) and/or shorter dosing interval (q8 weeks) was allowed.
(10 mg/kg) i/ili kraći interval između dvije doze (8 tjedana).
Each Remsima vial contains 100 mg infliximab.
Jedna bočica lijeka Remsima sadrži 100 mg infliksimaba.
Complement factor abnormal.
odstupanje od normalne vrijednosti faktora komplementa
During Remsima treatment, other concomitant therapies, e.g. corticosteroids and immunosuppressants should be optimised.
Tijekom liječenja lijekom Remsima treba optimalno prilagoditi istodobnu terapiju drugim lijekovima,
s r.o.
Za ACR-N
Remsima, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in:
Reumatoidni artritis Remsima je u kombinaciji s metotreksatom indicirana za smanjivanje znakova i simptoma te poboljšavanje fizičkih funkcija u: • odraslih bolesnika s aktivnom bolešću čiji odgovor na antireumatske lijekove koji modificiraju tijek bolesti (engl. disease-modifying antirheumatic drugs, DMARD), uključujući metotreksat,
Breast-feeding
bradikardija
Please follow these steps:
Molimo slijedite ove korake: Korak 1.
The active substance in Rheumocam is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) 37/2010:
Aktivna tvar u Rheumocamu je dopuštena tvar kao što je opisano u tablici 1 dodatka Uredbe Komisije (EU) br. 37/2010:
Agroseed Candilidis SA. Exit 1 of Attica Road, Thesi Xero Pigadi, Attikis 19600
Exit 1 of Attica Road, Thesi Xero Pigadi, Attikis 19600
60) blister packs with a 20 micron foil.
60) blister pakiranjima s 20 mikronskom folijom.
Ποζειδώνος 77 174 55 Άλιμος, Αηηική
Ποσειδώνος 77 174 55 Άλιμος, Αττική
The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this product.
Pomoćne tvari navedene u dijelu 6.1 SPC ili su dozvoljene tvari za koje je u tablici 1 Dodatka Uredbe Komisije (EU) br. 37/2010 naznačeno da određivanje MRL nije nužno, ili se smatra da se na njih ne primjenjuju odredbe Uredbe (EK) br. 470/2009 kada se primjenjuju u tom veterinarsko-medicinskom proizvodu.
Date of first authorisation: 10/01/2008.
Datum prvog odobrenja: 10/01/2008.
Rheumocam chewable tablets can be administered with or without food, are flavoured and are taken by most dogs voluntarily.
Rheumocam tablete za žvakanje mogu se davati s hranom ili bez nje, aromatizirane su i većina pasa ih uzima dragovoljno.
None.
Nijedan.
Each chewable tablet can be halved for accurate dosing according to the individual body weight of the animal.
Svaka tableta za žvakanje može se prepoloviti radi točnog doziranja u skladu s tjelesnom težinom pojedinog psa.
Date of last renewal: 18/12/2012.
Datum posljednjeg produljenja odobrenja: 18/12/2012.
PB 3 08960.
Constitución 1. PB 3 08960.
Date of first authorisation: 10/01/2008 Date of last renewal: 18/12/2012
Datum prvog odobrenja: 10/01/2008 Datum posljednjeg produljenja odobrenja: 18/12/2012
This product is only for use in horses weighing between 500 and 600 kg.
Ovaj proizvod je samo za uporabu kod konja koji teže između 500 i 600 kg.
ATCvet code: QM01AC06.
ATKvet kod: QM01AC06
The syringe has a scale which corresponds to the volume required.
Šprica ima mjernu skalu, koja odgovara zahtijevanoj dozi.
Rheumocam chewable tablets are supplied in:
Rheumocam tablete za žvakanje se isporučuju u:
The following dosing table indicates what volume to administer depending on the weight of the dog:
Sljedeća tablica pokazuje doziranje za primjenu ovisno o težini psa:
In order to minimise risk of intolerance, the product should be mixed into muesli feed.
Kako bi se smanjio rizik od netolerancije, proizvod treba miješati u müsli hranu.
The major metabolites found in all species were the 5-hydroxyand 5-carboxy- metabolites and the oxalyl- metabolite.
Osnovni metaboliti nađeni u svih vrsta bili su 5-hidroksi- i 5-karboksimetaboliti te oksalil-metabolit.
Non-infectious locomotor disorders.
Neinfekcijski poremećaji lokomotornog sustava.
After administration of the veterinary medicinal product, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.
Nakon primjene veterinarskog medicinskog proizvoda, zatvorite bocu zamjenom kape, operite špricu za mjerenje s toplom vodom i ostavite da se osuši.
10, Iasi 707410
Tg.Frumos, km. 10, Iasi 707410
For the first day, twice the maintenance dosage will be required.
Stoga će prvi dan liječenja biti potrebna dvostruka doze održavanja.
Dosage for each species:
Doze za svaku životinjsku vrstu
Cardboard box
Kartonskoj kutiji
For dogs weighing less than 4 kg the use of Rheumocam oral suspension for dogs is recommended.
Za pse težine manje od 4 kg, preporučuje se primjena Rheumocam peroralne suspenzije za pse.
For example, a horse weighing 400 kg will receive 16 ml of Rheumocam, a horse weighing 500 kg will receive 20 ml of Rheumocam, and a horse weighing 600 kg will receive 24 ml of Rheumocam.
Na primjer, konj težak 400 kg će primiti 16 ml Rheumocama, konj težak 500 kg će primiti 20 ml Rheumocama, a konj težila 600 kilograma će primiti 24 ml Rheumocama.
Apple flavour (containing butylated hydroxyanisole (E320)) Crospovidone
Okus jabuke (sadrži butilirani hidroksianisol (E320)) Krospovidon.
NePhar - Farma, Lda R. Francisco Lyon de Castro, 28 2725-397 Mem Martins
Francisco Lyon de Castro, 28 2725-397 Mem Martins
Pack sizes: 20 and 100 tablets.
Pakiranja: 20 i 100 tableta.
Maintenance dosage (ml)
Održavanje doziranje (ml)
This is equivalent to 1 ml of Rheumocam per 25 kg body weight of horse.
To je ekvivalent za 1 ml Rheumocam po 25 kg tjelesne težine konja.
Shelf life after incorporation into muesli feed: use immediately.
Rok valjanosti nakon ugradnje u müsli hranu: koristiti odmah.
Treatment of piglets with Rheumocam before castration reduces post-operative pain.
Primjena Rheumocama u prasadi prije kastracije smanjuje bol poslije zahvata.
Glucose monohydrate
Glukoza monohidrat
Replace the cap on the bottle and shake it well.
Vratite poklopac na bocu i dobro protresite.
Each bottle is packed in a cardboard box with a 1 ml measuring syringe (barrel in polypropylene and plunger/piston in high density polyethylene).
Svaka boca pakirana je u kartonsku kutiju s mjernom špricom od 1 mL (polipropilenske cijevi i polietilenske klipove / klip visoke gustoće.
Paper foil sachets (paper/PE/alu/PE) containing 1.5 g granules per sachet in a cardboard box with 100 sachets.
Vrećice od papirnate folije (papir/PE/alu/PE) sadrže 1,5 g granula po vrećici u kartonskoj kutiji s 100 vrećica.
PHARMACEUTICAL FORM
FARMAKOLOŠKI OBLIK
In cattle and pigs, subcutaneous, intramuscular as well as intravenous administration is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in less than 10 % of the cattle treated in clinical studies.
U goveda i svinja dobro se podnosi supkutana, intramuskularna a također i intravenska primjena; samo lagano prolazno oticanje na mjestu uboda nakon supkutane primjene opaženo je u manje od 10% goveda liječenih u sklopu kliničkih ispitivanja.
In case of inadequate relief of pain when used in the treatment of equine colic, careful re-evaluation of the diagnosis should be made as this could indicate the need for surgical intervention.
U slučaju nedjelovanja bolova u liječenju konjskih kolika, potrebno je ponovo pažljivo procijeniti dijagnozu jer bi to moglo upućivati na potrebu kirurškog zahvata.
Pack size: 100 sachets.
Veličina pakovanja: 100 vrećica.
Before using Rheumocam for the very first time ensure that you have the bottle, circular plastic insert and syringe.
Prije prve upotrebe Rheumocama, provjerite da imate bočicu, kružni plastični umetak i štrcaljki.
Any oral follow-up therapy using meloxicam or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should not be administered in cats, as appropriate dosage regimens for such follow-up treatments have not been established.
Nastavak liječenja u obliku peroralne terapije meloksikamom ili drugim nesteroidnim protuupalnim lijekovima (NSAID) ne smije se primjenjivati u mačaka, jer za takva liječenja nisu ustanovljeni odgovarajući dozni režimi.
One chewable tablet contains:
Jedna tableta za žvakanje sadrži:
Diarrhoea in calves of over one week of age and young, non-lactating cattle.
Proljev u teladi starije od tjedan dana i mladih goveda koja nisu u laktaciji.
Reduction of post-operative pain (over a period of 24 hours): single intravenous or subcutaneous injection before surgery, for example, at the time of induction of anaesthesia.
Smanjenje poslijeoperativnih bolova (u razdoblju od 24 sata): jedna intravenska ili supkutana injekcija prije kirurškog zahvata, primjerice u vrijeme uvođenja u anesteziju.
Eurovet Animal Health B.V., Handelsweg 25, 5531 AE Bladel, The Netherlands
Eurovet Animal Health B.V., Handelsweg 25, 5531 AE Bladel, Nizozemska
Place the circular plastic insert into the neck of the bottle and push down until securely in place.
Postavite kružni plastični umetak na grlić bočice i gurnite prema dolje dok čvrsto ne sjedne.
Smooth light yellow suspension.
Glatka svijetlo žuta suspenzija
Once in place the insert will not need to be removed.
Jednom postavljen, ne treba se skidati.
- Ethanol (96%) - Poloxamer 188 - Macrogol 400 - Glycine - Disodium edetate - Sodium hydroxide - Hydrochloric acid, concentrated - Meglumine - Water for injections
- etanol (96%) - poloksamer 188 - makrogol 400 - glicin - disodium edetate - natrijev hidroksid - hidroklorna kiselina - meglumin - voda za injekcije
To be administered orally either mixed with food or directly into the mouth.
Primjenjuje se ili izmiješano s s hranom, ili izravno u usta.